In the realm of medical research, the intricate interplay of epidemiological risk, genomic activity, adverse events, and clinical response necessitates a nuanced consideration of multiple variables. Clinical trials, designed to meticulously assess the efficacy and safety of interventions, routinely incorporate a diverse array of endpoints. While a primary endpoint is customary, supplemented by key secondary endpoints, the statistical significance is typically evaluated independently for each. To address the inherent challenges in studying multiple endpoints, diverse strategies, including composite endpoints and global testing, have been proposed. This work stands apart by focusing on the evaluation of a clinical trial, deviating from the conventional approach to underscore the efficacy of a multiple-endpoint procedure. A double-blind study was conducted to gauge the treatment efficacy in adults infected with human immunodeficiency virus type 1 (HIV-1), featuring CD4 cell counts ranging from 200 to 500 per cubic millimeter. A total of 2467 HIV-1-infected patients (43 percent without prior antiretroviral treatment) were randomly assigned to one of four daily regimens: 600 mg of zidovudine; 600 mg of zidovudine plus 400 mg of didanosine; 600 mg of zidovudine plus 2.25 mg of zalcitabine; or 400 mg of didanosine. The primary endpoint comprised a >50 percent decline in CD4 cell count, development of acquired immunodeficiency syndrome (AIDS), or death. This study sought to determine the efficacy and safety of zidovudine (AZT) versus didanosine (ddI), AZT plus ddI, and AZT plus zalcitabine (ddC) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3. By jointly considering all endpoints, the multiple-endpoints approach yields results of greater significance than a single-endpoint approach.

翻译：在医学研究领域，流行病学风险、基因组活性、不良事件与临床反应之间的复杂相互作用要求对多种变量进行细致考量。旨在严格评估干预措施疗效与安全性的临床试验，通常会纳入多样化的终点指标。尽管主要终点是常规设定，并辅以关键次要终点，但其统计显著性通常针对每个终点独立评估。为应对研究多终点所固有的挑战，学术界提出了多种策略，包括复合终点和全局检验。本研究区别于常规方法，专注于临床试验评估，旨在突出多终点程序的效能。研究采用双盲设计，衡量感染人类免疫缺陷病毒1型（HIV-1）、CD4细胞计数范围为每立方毫米200至500个的成人患者的治疗效果。总计2467名HIV-1感染者（其中43%既往未接受过抗逆转录病毒治疗）被随机分配至四种每日治疗方案之一：600毫克齐多夫定；600毫克齐多夫定联合400毫克去羟肌苷；600毫克齐多夫定联合2.25毫克扎西他滨；或400毫克去羟肌苷。主要终点包括CD4细胞计数下降超过50%、出现获得性免疫缺陷综合征（艾滋病）或死亡。本研究旨在确定齐多夫定（AZT）对比去羟肌苷（ddI）、AZT联合ddI以及AZT联合扎西他滨（ddC）在预防CD4计数为200-500个/立方毫米的HIV感染者疾病进展方面的疗效与安全性。通过联合考量所有终点，多终点方法相比单终点方法能够得出更具显著性的结果。